Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 90 | ECE2023 | Next issue

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

Card image cap
ECE 2023 will be held in Istanbul, Turkey from 13-16 May 2023. Istanbul is known for its rich culture, historical sites and dynamic nightlife, and we are excited to come together in this city, and look forward to meeting old friends, making new ones, and sharing science, collaborations and ideas.

Rapid Communications

Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2

ea0090rc10.1 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

Gold and cerium oxide nanoparticles reduce liver steatosis and inflammation in rats with steatohepatitis

Casals Gregori , Lecue Elena , Shahbazi Shayan , Guo Dongdong , Perramon Meritxell , Zeng Muling , Jimenez Wladimiro , Morales-Ruiz Manuel , Casals Eudald , Fernandez-Varo Guillermo

Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by the presence of hepatic steatosis, which can progress to non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma. There are no licensed therapies to halt MAFLD progression, despite it is becoming the most important etiology for advanced liver disease.Aim: The aim of the study was to evaluate the therapeutic potential of inorganic nanopartic...

ea0090rc10.2 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

Increased risk of cirrhosis in post-menopausal women with NAFLD

Izzi-Engbeaya Chioma , Eng Pei , Dunin-Borkowska Aleksandra , Forlano Roberta , Mullish Benjamin H , Sigon Giordano , Lin Vicky , Tan Tricia , Yee Michael , Manousou Pinelopi , Dhillo Waljit

Background: Non-alcoholic liver disease (NAFLD) affects up to 30% of adults worldwide. With the prevalence of NAFLD increasing after menopause, women aged >55 years are more likely to progress to advanced fibrosis than men. Moreover, liver decompensation secondary to NAFLD is more frequent in women compared to men. However, the causes of these differential outcomes are not fully understood.Methodology: We performed a retrospective cohort study utilis...

ea0090rc10.3 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: A 2-year observational study

Jensterle Mojca , Ferjan Simona , Goricar Katja , Janez Andrej

Background: Withdrawal of anti-obesity medication is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. In STEP 1 trial extension participants regained two-thirds of their prior weight loss during the 1-year off-treatment follow-up period after withdrawal of semaglutide 2.4 mg and discontinuation of active lifestyle intervention support. There are some studies implying that metformin might attenuat...

ea0090rc10.4 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

Kisspeptin does not have detrimental metabolic effects in women

Izzi-Engbeaya Chioma , Choudhury Muhammad , Patel Bijal , Muzi Beatrice , Qayum Ambreen , Mills Edouard G , Ahsan Maheen , Phylactou Maria , Clarke Sophie , Aslett Laura , Comninos Alexander , Abbara Ali , Tan Tricia , Dhillo Waljit

Background: There is emerging evidence that kisspeptin, a hormone with well-established reproductive effects, may also have important metabolic effects. Acute kisspeptin administration enhances insulin secretion under hyperglycaemic conditions in male rodents and men, and kisspeptin receptor agonism improves steatohepatits in male mice in a rodent model of non-alcoholic fatty liver disease. However, the metabolic effects of kisspeptin may exhibit sexual dimorphism as female (b...

ea0090rc10.5 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

Metformin counteracts adverse metabolic effects of glucocorticoids in healthy subjects

Thierry Susanne , Peterson Caspar Joyce , Delko Tarik , Iten Vasco , Epstein Michael , Kuhne Michael , Meyer-Zurn Christine , Seelig Eleonora

Background: Glucocorticoids are powerful anti-infla mmatory drugs. However, metabolic side effects are common and limit their long-term use. Furthermore, the underlying mechanisms of adverSemetabolic effects are not well known, and this lack of knowledge results in poor treatment. We have previously shown that the antidiabetic drug metformin prevents glucocorticoid-induced metabolic effects in older, sick patients. Here, we investigate metformin in a young and healthy populati...

ea0090rc10.6 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

Childhood and adolescent obesity associated with classic congenital adrenal hyperplasia and 21-hydroxylase deficiency

Kumar Naween , Jha Sudhir Chandra

Introduction: The most prevalent hereditary disease of adrenal steroid production is congenital adrenal hyperplasia (CAH), which is caused by a 21-hydroxylase deficiency. With or without salt wasting, patients with the typical form of CAH exhibit androgen excess. Leptin participates in endocrine and metabolic processes in addition to controlling energy balance. This study examined BMI values for children and teens with CAH in comparison to population-based benchmarks. Current ...